Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

9 décembre 2015 mis à jour par: Bristol-Myers Squibb

A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA

The primary purpose of the protocol is to demonstrate the ability of abatacept plus methotrexate to induce remission in patients with very early rheumatoid arthritis after 12 months of treatment and to maintain remission following 6 months of drug withdrawal.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

511

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Afrique du Sud
    • Gauteng
      • Kempton Park, Gauteng, Afrique du Sud, 1619
        • Local Institution
      • Pretoria, Gauteng, Afrique du Sud, 0083
        • Local Institution
      • Pretoria, Gauteng, Afrique du Sud, 0084
        • Local Institution
      • Pretoria, Gauteng, Afrique du Sud, 0181
        • Local Institution
    • Kwa Zulu Natal
      • Durban, Kwa Zulu Natal, Afrique du Sud, 4001
        • Local Institution
    • Western Cape
      • Panorama, Western Cape, Afrique du Sud, 7500
        • Local Institution
  • Allemagne
      • Berlin, Allemagne, 10117
        • Local Institution
      • Berlin, Allemagne, 14059
        • Local Institution
      • Hildesheim, Allemagne, 31134
        • Local Institution
      • Muenchen, Allemagne, 80336
        • Local Institution
      • Muenchen, Allemagne, 80639
        • Local Institution
      • Muenchen, Allemagne, 81541
        • Local Institution
  • Australie
    • Queensland
      • Cairns, Queensland, Australie, 4870
        • Local Institution
      • Maroochydore, Queensland, Australie, 4558
        • Local Institution
    • South Australia
      • Woodville, South Australia, Australie, 5011
        • Local Institution
    • Victoria
      • Heidelberg, Victoria, Australie, 3084
        • Local Institution
      • Malvern, Victoria, Australie, 3144
        • Local Institution
    • Western Australia
      • Victoria Park, Western Australia, Australie, 6100
        • Local Institution
  • Belgique
      • Bruxelles, Belgique, 1200
        • Local Institution
      • Kortrijk, Belgique, 8500
        • Local Institution
      • Merksem, Belgique, 2170
        • Local Institution
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N1
        • Local Institution
    • Quebec
      • Laval, Quebec, Canada, H7T 2P5
        • Local Institution
  • Corée, République de
      • Daegu, Corée, République de, 705-718
        • Local Institution
      • Daejeon, Corée, République de, 302-799
        • Local Institution
      • Seoul, Corée, République de, 137-701
        • Local Institution
      • Seoul, Corée, République de, 133-791
        • Local Institution
  • Danemark
      • Hjorring, Danemark, 9800
        • Local Institution
  • Finlande
      • Helsinki, Finlande, 00290
        • Local Institution
      • Tampere, Finlande, 33521
        • Local Institution
  • France
      • Chambray Les Tours, France, 37170
        • Local Institution
      • Montpellier, France, 34295
        • Local Institution
      • Paris Cedex 14, France, 75679
        • Local Institution
      • Poitiers, France, 86021
        • Local Institution
  • Fédération Russe
      • Moscow, Fédération Russe, 117049
        • Local Institution
      • Moscow, Fédération Russe, 129327
        • Local Institution
      • Tver, Fédération Russe, 170036
        • Local Institution
  • Italie
      • Ancona, Italie, 60055
        • Local Institution
      • Siena, Italie, 53100
        • Local Institution
  • Mexique
      • Chihuahua, Mexique, 31000
        • Local Institution
      • Queretaro, Mexique, 76178
        • Local Institution
      • San Luis Potosi, Mexique, 78240
        • Local Institution
    • Estado De Mexico
      • Metepec, Estado De Mexico, Mexique, 52140
        • Local Institution
    • Jalisco
      • Guadalajara, Jalisco, Mexique, 44500
        • Local Institution
      • Guadalajara, Jalisco, Mexique, 44690
        • Local Institution
    • Nuevo Leon
      • Monterrey, Nuevo Leon, Mexique, 64020
        • Local Institution
    • Yucatan
      • Merida, Yucatan, Mexique, 97000
        • Local Institution
  • Pologne
      • Lublin, Pologne, 20-954
        • Local Institution
      • Poznan, Pologne, 60-218
        • Local Institution
      • Torun, Pologne, 87100
        • Local Institution
      • Warszawa, Pologne, 01-157
        • Local Institution
      • Warszawa, Pologne, 01-868
        • Local Institution
      • Wroc#aw, Pologne, 50-088
        • Local Institution
  • Suède
      • Goteborg, Suède, 413 45
        • Local Institution
      • Linkoping, Suède, 581 85
        • Local Institution
      • Malmo, Suède, 205 02
        • Local Institution
      • Stockholm, Suède, 171 76
        • Local Institution
      • Uppsala, Suède, 751 85
        • Local Institution
  • États-Unis
    • Alabama
      • Huntsville, Alabama, États-Unis, 35801
        • Rheumatology Associates Of North Alabama, P.C.
    • Arkansas
      • Hot Springs, Arkansas, États-Unis, 71913
        • St. Joseph'S Mercy Clinic
    • Florida
      • Sarasota, Florida, États-Unis, 34239
        • Sarasota Arthritis Research Center
    • Idaho
      • Coeur D Alene, Idaho, États-Unis, 83814
        • Coeur D'Alene Arthrit Clin
    • Maryland
      • Baltimore, Maryland, États-Unis, 21224
        • Johns Hopkins University Division of Rheumatology
    • Massachusetts
      • Worcester, Massachusetts, États-Unis, 01605
        • Clinical Pharmacology Study Group
    • Mississippi
      • Jackson, Mississippi, États-Unis, 39202
        • Arthritis Associates Of Mississippi
    • Nebraska
      • Lincoln, Nebraska, États-Unis, 68516
        • Physician Research Collaboration, LLC
    • North Carolina
      • Hickory, North Carolina, États-Unis, 28602
        • Piedmont Rheumatology, Pa
      • Wilmington, North Carolina, États-Unis, 28401
        • Carolina Arthritis Associates
    • Ohio
      • Cleveland, Ohio, États-Unis, 44109
        • MetroHealth Medical Center
      • Middleburg, Ohio, États-Unis, 44130
        • Isam A. Diab, Md
    • Pennsylvania
      • Duncansville, Pennsylvania, États-Unis, 16635
        • Alan J. Kivitz, Md, Cpi
    • South Carolina
      • Orangeburg, South Carolina, États-Unis, 29118
        • Mitchell C. Feinman, Md
    • Wisconsin
      • Glendale, Wisconsin, États-Unis, 53217
        • Kurt Oelke, Md

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  • Presence of active clinical synovitis in at least 2 joints, 1 of which must have been a small joint, for a minimum of 8 weeks prior to screening
  • Onset of persistent symptoms ≤ 2 years prior to screening
  • Positive test result for anticyclic citrullinated peptides 2
  • Methotrexate naive or with minimum exposure to methotrexate, defined as no more than 10 mg/week for ≤4 weeks and no methotrexate dose for 1 month prior to screening visit
  • Biologic naive, including no treatment with an investigational biologic prior to screening
  • Disease Activity Score 28 based on C-reactive protein score ≥3.2 at screening
  • Withdrawal from any treatment with chloroquine, hydroxychloroquine, and/or sulfasalazine (wash-out) for a minimum of 28 days prior to randomization
  • If receiving oral corticosteroids, on a stable low dose (≤ 10 mg/day prednisone equivalent) for at least 4 weeks
  • Able to undergo magnetic resonance imaging

Key Exclusion Criteria:

  • Meeting diagnostic criteria for other rheumatic disease (eg, lupus erythematosus)
  • Treatment with an intravenous, intramuscular, or intraarticular corticosteroid within 4 weeks prior to randomization
  • Scheduled for or anticipating joint replacement surgery
  • Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator
  • History of malignancy in the last 5 years
  • Any serious bacterial infection within the last 3 months not treated or resolved with antibiotics, or any chronic or recurrent bacterial infection
  • At risk for tuberculosis
  • Evidence of active or latent bacterial or viral infection at the time of potential enrollment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrollment

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Abatacept, 125 mg, plus methotrexate, 2.5 mg
Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
Médicament: Abatacept
Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
Autres noms:
  • Orencia
  • BMS 188667
Médicament: Methotrexate
Tablets, oral, 2.5 mg, once weekly, 12 months
Autres noms:
  • Rhumatrex
Comparateur actif: Methotrexate, 2.5 mg, plus abatacept placebo
Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
Médicament: Methotrexate
Tablets, oral, 2.5 mg, once weekly, 12 months
Autres noms:
  • Rhumatrex
Médicament: Abatacept placebo
Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
Comparateur actif: Abatacept, 125 mg, plus methotrexate placebo
Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
Médicament: Abatacept
Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
Autres noms:
  • Orencia
  • BMS 188667
Médicament: Methotrexate placebo
Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
Délai: Randomization to Months 12 and 18
DAS28-CRP remission defined as <2.6; TP=treatment phase; WP=withdrawal phase. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Randomization to Months 12 and 18

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Percentage of Participants Who Received Monotherapy and Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18
Délai: Randomization to Months 12 and 18
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Randomization to Months 12 and 18
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time - Intent to Treat Population
Délai: Randomization to Month 24
TP=treatment period; WP=withdrawal period. Remission defined as DAS28-CRP<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Randomization to Month 24
Adjusted Mean Change From Baseline in Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) at Months 6, 12, and 18
Délai: Baseline to Month 18
TP=treatment period; WP=withdrawal period. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) that assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)
Baseline to Month 18
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) at Months 12 and 18
Délai: Randomization to Month 18
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI <=3.3 indicates disease remission, >3.4 to 11=low disease activity, >11 to 26=moderate disease activity, and >26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity.
Randomization to Month 18
Adjusted Mean Change From Baseline in Scores on Simplified Disease Activity Index (SDAI) Over Time
Délai: Randomization to Month 18
TP=treatment period; WP=withdrawal period. The SDAI is the simple linear sum of 5 outcome parameters: swollen joint count (SJC) and tender joint count (TJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SJC is assessed and recorded at each visit, with no swelling=0, swelling=1 (higher score indicates greater swelling). TJC is assessed at each visit through identification of joints that are painful under pressure or to passive motion, with no tenderness=0, tenderness=1 (higher score indicates greater affection due to disease activity)..
Randomization to Month 18
Percentage of Participants Achieving a Health Assessment Questionnaire (HAQ) Response Over Time
Délai: Randomization to Month 24
HAQ response defined as a reduction of at least 0.3 units from baseline in score on the Health Assessment Questionnaire Disability Index (HAQ-DI), which assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
Randomization to Month 24
Adjusted Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Over Time
Délai: Randomization to Month 18
The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. The HAQ-DI includes at least 2 questions from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. When aids, devices, or help is indicated by the patient, the score for the category item is raised from a 0 or a 1 to a 2, but if the patient's highest score for a subcategory is a 3, it stays a 3.
Randomization to Month 18
Adjusted Mean Change From Baseline at Months 6, 12, and 18 in Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores of Short Form-36 (SF-36)
Délai: Randomization to Months 6, 12, and 18
TP=treatment period; WP=withdrawal period. The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
Randomization to Months 6, 12, and 18
Adjusted Mean Change From Baseline Over Time in Findings on Magnetic Resonance Imaging (MRI)
Délai: Randomization to Month 18
TP=treatment period; WP=withdrawal period. Change from Baseline=Postbaseline-baseline value. MRI was used to assess joint damage progression at Months 6, 12, and 18. If >20% of joints with a missing score for a parameter (erosion, osteitis, and synovitis), the MRI score of each parameter was considered missing. If ≤20% of joints had a missing score for a parameter, the MRI score for that parameter from the missing joints was carried forward from the previous MRI assessment, or carried backward from the next MRI assessment, if missing score occurred at baseline. MRI total score ranged from 0 (best outcome) to 4 (worst outcome). A gadolinium-enhanced MRI of the dominant hand-wrist was performed on all randomized patients at 5 points. The hand/wrist assessed to have more synovitis was selected initially and used for all subsequent evaluations. The MRI examination was standardized to ensure sufficient image quality for the evaluation of radiographic progression of rheumatoid arthritis.
Randomization to Month 18
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Related SAEs, Discontinuations Due to SAEs, Related Adverse Events (AEs), and Discontinuations Due to AEs During the Treatment Period
Délai: Day 1 to up to 56 days following the last dosing day (Day 365); all deaths during study period, including those that occurred >56 days after last dose in Treatment Period
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug.
Day 1 to up to 56 days following the last dosing day (Day 365); all deaths during study period, including those that occurred >56 days after last dose in Treatment Period
Adverse Events (AEs) of Interest During the Treatment Period
Délai: Day 1 to 56 days following last dosing day (Day 365)
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. AEs of special interest are events potentially associated with the drug or disease under study.
Day 1 to 56 days following last dosing day (Day 365)
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality During Treatment Period
Délai: Day 1 up to 56 days following the last dosing day in the Treatment Period (Day 365)
Lower limit of normal (LLN); Upper limit of normal (ULN); Pretreatment (preRX). Criteria for marked abnormality: Platelet count (*10^9 c/µL) <0.67*LLN or >1.5*ULN, or if preRX<LLN, use 0.5*preRX and <100,000/mm^3; potassium, serum (mEq) <0.9*LLN or >1.1*ULN, or if preRX <LLN, use <0.9*preRX or >ULN if preRX>ULN, use >1.1*preRX or <LLN; blood urea nitrogen (mg/dL) >2*preRX; creatinine (mg/dL) >1.5*preRX; ALT (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; AST (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; ALP (U/L) >2*ULN, or if preRX>ULN, use >3*preRX; G-glutamyl transferase U/L) >2*ULN, or if preRX>ULN, use >3*preRX; glucose, fasting (mg/dL) <0.8*LLN or >1.5*ULN, or if preRX<LLN use <0.8*preRX or >ULN if preRX >ULN, use >2.0*preRX or OR <LLN; glucose, serum (mg/dL) <65 or >220; uric acid (mg/dL)>1.5*ULN, or if preRX, use >2*preRX; albumin (g/dL) <0.9*LLN, or if preRX<LLN, use <0.75*preRX; hemoglobin (g/dL)>3 decrease from preRX; hematocrit (%) < 0.75*preRX.
Day 1 up to 56 days following the last dosing day in the Treatment Period (Day 365)
Percentage of Participants With Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria Over Time During Withdrawal Period- Treated Participants in Remission at Month 12
Délai: End of Treatment Period (Month 12) to End of Withdrawal Period (Month 24)
WP=withdrawal period. Remission defined as DAS28-CRP<2.6. The DAS 28-CRP is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). DAS-CRP scores range from 0 to 10, with higher values indicating greater disease activity. Individual measures are fed into a complex mathematical formula to produce the overall DAS (a score greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.). Percentage= number of participants with remission divided by number of participants who were analyzed (all treated participants who were in remission at end of treatment period and entered the Withdrawal Period)
End of Treatment Period (Month 12) to End of Withdrawal Period (Month 24)
Percentage of Participants Who Achieved Remission by Criteria of the Simplified Disease Activity Index (SDAI) Over Time in Treatment Period and Withdrawal Period
Délai: Randomization to Month 24
TP=treatment period; WP=withdrawal period. SDAI-defined remission= ≤3.3. The SDAI is the simple linear sum of 5 outcome parameters: tender joint count (TJC) and swollen joint count (SJC) (based on a 28-joint assessment); patient's and physician's global assessments of disease activity (assessed on 0-10 cm visual analog scale, on which higher scores=greater affection due to disease activity); and C-reactive protein level (mg/dL). SDAI total score=0-86. SDAI <=3.3 indicates disease remission, >3.4 to 11=low disease activity, >11 to 26=moderate disease activity, and >26=high disease activity. TJC is assessed and recorded at each visit, with no swelling=0, swelling=1. SJC is assessed through identification of joints that are painful under pressure or to passive motion. TJC is recorded on the joint assessment form at each visit, with no tenderness =0, tenderness = 1. Higher score indicates greater affection due to disease activity. Percent=number with remission/number evaluated (ITT)
Randomization to Month 24
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) and Discontinuations Due to AEs During the Full Study (All Periods)
Délai: Day 1 to 56 days post last dose in the study, up to Month 30
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Includes data up to last active dose date +56 days if the participant discontinued the Treatment Period or did not enter the Withdrawal Period, up to the day of discontinuation in the Withdrawal Period for participants discontinuing the Withdrawal Period without entering the Re-exposure Period (RP), up to Day 729 visit (Month 24) for participants who complete the Withdrawal Period, and up to 56 days post last active dose in Re-exposure Period for participants entering the Re-exposure Period.
Day 1 to 56 days post last dose in the study, up to Month 30
Adverse Events (AEs) of Interest During the Withdrawal Period
Délai: Last dose in TP + 57 days, up to Month 24
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes events with an onset date on or after 57 days post last dosing day (active abatacept or active MTX whichever is the later) in the Treatment Period and up to end of Withdrawal Period. Treatment groups represent treatment received during the Treatment Period.
Last dose in TP + 57 days, up to Month 24
Adverse Events (AEs) of Interest During the Re-exposure Period
Délai: First dose in Re-exposure period up to last dose of Re-exposure Period + 56 days
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AEs of special interest are events potentially associated with the drug or disease under study. Includes data up to 56 days post the last dosing day (active abatacept or active MTX, whichever is the later) in the Re-exposure Period. Treatment groups represent Treatment received during Treatment Period.
First dose in Re-exposure period up to last dose of Re-exposure Period + 56 days
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Withdrawal Period
Délai: Last dose in TP + 57 days, up to Month 24
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (*10^9 c/µL) <0.67*LLN or >1.5*ULN, or if preRX<LLN, use 0.5*preRX and <100,000/mm^3; potassium, serum (mEq) <0.9*LLN or >1.1*ULN, or if preRX <LLN, use <0.9*preRX or >ULN if preRX>ULN, use >1.1*preRX or <LLN; blood urea nitrogen (mg/dL) >2*preRX; creatinine (mg/dL) >1.5*preRX; ALT (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; AST (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; ALP (U/L) >2*ULN, or if preRX>ULN, use >3*preRX; G-glutamyl transferase (GGT) (U/L) >2*ULN, or if preRX>ULN, use >3*preRX; glucose, fasting (mg/dL) <0.8*LLN or >1.5*ULN, or if preRX<LLN use <0.8*preRX or >ULN if preRX >ULN, use >2.0*preRX or OR <LLN; glucose, serum (mg/dL) <65 or >220; uric acid (mg/dL)>1.5*ULN, or if preRX, use >2*preRX; albumin (g/dL) <0.9*LLN, or if preRX<LLN, use <0.75*preRX; hemoglobin (g/dL)>3 decrease from preRX; hematocrit (%) < 0.75*preRX.
Last dose in TP + 57 days, up to Month 24
Number of Participants With Results on Hematology and Clinical Laboratory Tests Meeting the Criteria for Marked Abnormality in Re-exposure Period
Délai: Start of re-exposure period to 56 days post last dose, up to Month 30
LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Criteria for marked abnormality on laboratory test results: Platelet count (*10^9 c/µL) <0.67*LLN or >1.5*ULN, or if preRX<LLN, use 0.5*preRX and <100,000/mm^3; potassium, serum (mEq) <0.9*LLN or >1.1*ULN, or if preRX <LLN, use <0.9*preRX or >ULN if preRX>ULN, use >1.1*preRX or <LLN; blood urea nitrogen (mg/dL) >2*preRX; creatinine (mg/dL) >1.5*preRX; ALT (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; AST (U/L) >3*ULN, or if preRX>ULN, use >4*preRX; ALP (U/L) >2*ULN, or if preRX>ULN, use >3*preRX; G-glutamyl transferase U/L) >2*ULN, or if preRX>ULN, use >3*preRX; glucose, fasting (mg/dL) <0.8*LLN or >1.5*ULN, or if preRX<LLN use <0.8*preRX or >ULN if preRX >ULN, use >2.0*preRX or OR <LLN; glucose, serum (mg/dL) <65 or >220; uric acid (mg/dL)>1.5*ULN, or if preRX, use >2*preRX; albumin (g/dL) <0.9*LLN, or if preRX<LLN, use <0.75*preRX; hemoglobin (g/dL)>3 decrease from preRX; hematocrit (%) < 0.75*preRX.
Start of re-exposure period to 56 days post last dose, up to Month 30

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Bristol-Myers Squibb

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 décembre 2010

Achèvement primaire (Réel)

1 septembre 2013

Achèvement de l'étude (Réel)

1 octobre 2014

Dates d'inscription aux études

Première soumission

3 juin 2010

Première soumission répondant aux critères de contrôle qualité

10 juin 2010

Première publication (Estimation)

11 juin 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

14 janvier 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 décembre 2015

Dernière vérification

1 décembre 2015

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • IM101-226
  • 2010-018674-20 (Numéro EudraCT)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Abatacept

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Belgium

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner